Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions

Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS

Mehrdad Arjomandi, Siyang Zeng, Igor Barjaktarevic, R. Graham Barr, Eugene R. Bleecker, Russell P. Bowler, Russell G. Buhr, Gerard J. Criner, Alejandro P. Comellas, Christopher B. Cooper, David J. Couper, Jeffrey L. Curtis, Mark T. Dransfield, MeiLan K. Han, Nadia N. Hansel, Eric A. Hoffman, Robert J. Kaner, Richard E. Kanner, Jerry A. Krishnan, Robert Paine III, Stephen P. Peters, Stephen I. Rennard, Prescott G. Woodruff for the SPIROMICS Investigators
European Respiratory Journal 2019 54: 1802214; DOI: 10.1183/13993003.02214-2018
Mehrdad Arjomandi
San Francisco Veterans Affairs Healthcare System, San Francisco, CA, USADept of Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mehrdad.arjomandi@ucsf.edu
Siyang Zeng
San Francisco Veterans Affairs Healthcare System, San Francisco, CA, USADept of Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Igor Barjaktarevic
Dept of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Graham Barr
Columbia-Presbyterian Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene R. Bleecker
University of Arizona, College of Medicine, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell P. Bowler
National Jewish Health Systems, Denver, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Russell G. Buhr
Dept of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USAGreater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard J. Criner
Temple University, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro P. Comellas
University of Iowa, Iowa City, IA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher B. Cooper
Dept of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USADept of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Couper
University of North Carolina, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey L. Curtis
Medical Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, USADepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark T. Dransfield
University of Alabama at Birmingham, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MeiLan K. Han
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadia N. Hansel
Johns Hopkins Medical Institute, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric A. Hoffman
Dept of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Kaner
Weill Cornell Weill Cornell Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard E. Kanner
University of Utah, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry A. Krishnan
University of Illinois at Chicago, Chicago, IL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Paine
University of Utah, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen P. Peters
Wake Forest School of Medicine, Winston-Salem, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen I. Rennard
BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prescott G. Woodruff
Dept of Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The characteristics that predict progression to overt chronic obstructive pulmonary disease (COPD) in smokers without spirometric airflow obstruction are not clearly defined.

We conducted a post hoc analysis of 849 current and former smokers (≥20 pack–years) with preserved spirometry from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort who had baseline computed tomography (CT) scans of lungs and serial spirometry. We examined whether CT-derived lung volumes representing air trapping could predict adverse respiratory outcomes and more rapid decline in spirometry to overt COPD using mixed-effect linear modelling.

Among these subjects with normal forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio, CT-measured residual volume (RVCT) to total lung capacity (TLCCT) ratio varied widely, from 21% to 59%. Over 2.5±0.7 years of follow-up, subjects with higher RVCT/TLCCT had a greater differential rate of decline in FEV1/FVC; those in the upper RVCT/TLCCT tertile had a 0.66% (95% CI 0.06%–1.27%) faster rate of decline per year compared with those in the lower tertile (p=0.015) regardless of demographics, baseline spirometry, respiratory symptoms score, smoking status (former versus current) or smoking burden (pack–years). Accordingly, subjects with higher RVCT/TLCCT were more likely to develop spirometric COPD (OR 5.7 (95% CI 2.4–13.2) in upper versus lower RVCT/TLCCT tertile; p<0.001). Other CT indices of air trapping showed similar patterns of association with lung function decline; however, when all CT indices of air trapping, emphysema, and airway disease were included in the same model, only RVCT/TLCCT retained its significance.

Increased air trapping based on radiographic lung volumes predicts accelerated spirometry decline and progression to COPD in smokers without obstruction.

Abstract

Radiographic lung volumes and related computed tomography measures that represent air trapping are associated with an accelerated decline in lung function and can identify susceptible smokers at increased risk of progressing to overt COPD http://bit.ly/32QqiKQ

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Author contributions: Conceived and designed the current study: M. Arjomandi. Developed study protocols: M. Arjomandi, S. Zeng, I. Barjaktarevic, R.G. Barr, E.R. Bleecker, R.P. Bowler, R.G. Buhr, G.J. Criner, A.P. Comellas, C.B. Cooper, D.J. Couper, J.L. Curtis, M.T. Dransfield, M.K. Han, N.N. Hansel, E.A. Hoffman, R.J. Kaner, R.E. Kanner, J.A. Krishnan, R. Paine III, S.P. Peters, S.I. Rennard and P.G. Woodruff. Collected data: I. Barjaktarevic, R.G. Barr, E.R. Bleecker, R.P. Bowler, R.G. Buhr, G.J. Criner, A.P. Comellas, C.B. Cooper, D.J. Couper, J J.L. Curtis, M.T. Dransfield, M.K. Han, N.N. Hansel, E.A. Hoffman, R.J. Kaner, R.E. Kanner, J.A. Krishnan, R. Paine III, S.P. Peters, S.I. Rennard and P.G. Woodruff. Analysed and interpreted data: M. Arjomandi, S. Zeng, I. Barjaktarevic, R.G. Barr, R.P. Bowler, R.G. Buhr, A.P. Comellas, C.B. Cooper, D.J. Couper, J.L. Curtis, M.T. Dransfield, M.K. Han, N.N. Hansel, E.A. Hoffman, R.J. Kaner, R.E. Kanner, J.A. Krishnan, R. Paine III, S.P. Peters, S.I. Rennard and P.G. Woodruff. Prepared and edited the manuscript: M. Arjomandi, S. Zeng, I. Barjaktarevic, R.G. Barr, R.P. Bowler, R.G. Buhr, A.P. Comellas, C.B. Cooper, D.J. Couper, J.L. Curtis, M.T. Dransfield, M.K. Han, N.N. Hansel, E.A. Hoffman, R.J. Kaner, R.E. Kanner, J.A. Krishnan, R. Paine III, S.P. Peters, S.I. Rennard and P.G. Woodruff. Obtained funding: M. Arjomandi, I. Barjaktarevic, R.G. Barr, E.R. Bleecker, R.P. Bowler, R.G. Buhr, G.J. Criner, A.P. Comellas, C.B. Cooper, D.J. Couper, J.L. Curtis, M.T. Dransfield, M.K. Han, N.N. Hansel, E.A. Hoffman, R.J. Kaner, R.E. Kanner, J.A. Krishnan, R. Paine III, S.P. Peters, S.I. Rennard and P.G. Woodruff.

  • Support statement: SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune, Bayer, Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Forest Research Institute, Inc., GlaxoSmithKline, Grifols Therapeutics, Inc., Ikaria, Inc., Novartis Pharmaceuticals Corporation, Nycomed GmbH, ProterixBio, Regeneron Pharmaceuticals, Inc., Sanofi, Sunovion, Takeda Pharmaceutical Company and Theravance Biopharma. Funding for the work on this manuscript was also provided by the Flight Attendant Medical Research Institute (M. Arjomandi). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: S. Zeng reports salary support from United States Department of Veterans Affairs, during the conduct of the study.

  • Conflict of interest: I. Barjaktarevic reports grants from AMGEN, grants and personal fees from GE Healthcare, personal fees from Grifols, AstraZeneca, CSL Behring, Boehringer Ingelheim, Verona Pharma and Fisher and Pykel Healthcare, outside the submitted work.

  • Conflict of interest: R.G. Barr reports grants from NIH, Foundation for the NIH and COPD Foundation, during the conduct of the study; grants from Alpha1 Foundation, personal fees (royalties) from UpToDate, outside the submitted work.

  • Conflict of interest: E.R. Bleecker reports grants from SARP, AsthmaNET, SPIROMICS, Pharmacogenetics and Foundation NIH, involvement in clinical trials administered through Wake Forest School of Medicine for Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Genentech/Roche, GlaxoSmithKline, Janssen/Johnson & Johnson, Novartis, Pfizer, Sanofi-Regeneron and Teva, personal fees for consultancy from Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Genentech/Roche, GlaxoSmithKline, Knopp, Novartis and Sanofi/Regeneron, outside the submitted work.

  • Conflict of interest: R.P. Bowler reports having served on advistory boards for Boehringer-Ingelheim and Abbott Nutrition, outside the submitted work.

  • Conflict of interest: R.G. Buhr reports personal fees from GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: G.J. Criner has nothing to disclose.

  • Conflict of interest: A.P. Comellas reports grants from NIH, during the conduct of the study; non-financial support for consultancy from VIDA Diagnostics, outside the submitted work.

  • Conflict of interest: C.B. Cooper has nothing to disclose.

  • Conflict of interest: D.J. Couper reports grants from NHLBI (NIH) and COPD Foundation, during the conduct of the study; grants from NHLBI (NIH), outside the submitted work.

  • Conflict of interest: J.L. Curtis reports grants from NIH/NHLBI (U01HL137880), during the conduct of the study; and grants from Department of Veterans Affairs (I01 CX000911), NIH/NIAID (R01 AI120526, R21 AI 117371), Department of Defense (W81XWH-15-1-0705, PR150432) and MedImmune, Corp. Ltd, outside the submitted work.

  • Conflict of interest: M.T. Dransfield reports grants from NIH, during the conduct of the study; grants from Department of Defense, NIH and the American Lung Association, personal fees for consultancy and involvement with contracted clinical trials for Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, PneumRx/BTG and Boston Scientific, involvement with contracted clinical trials for Novartis, Yungjin and Pulmonx, personal fees for consultancy from Genentech, Quark Pharmaceuticals and Mereo, outside the submitted work.

  • Conflict of interest: M.K. Han reports personal fees from GSK, BI and AZ, non-financial support from Novartis and Sunovion, outside the submitted work.

  • Conflict of interest: N.N. Hansel reports grants and personal fees for consultancy from AstraZeneca and GSK, grants from Boehringer Ingelheim, NIH and COPD Foundation, personal fees for consultancy from Mylan, outside the submitted work.

  • Conflict of interest: E.A. Hoffman reports grants from NIH, during the conduct of the study; and is a founder and shareholder of VIDA Diagnostics, a company commercialising lung image analysis software developed, in part, at the University of Iowa.

  • Conflict of interest: R.J. Kaner reports personal fees from Boehringer Ingelheim, Roche/Genentech, Medimmune/AstraZeneca, Gilead, Celgene and Janssen, outside the submitted work.

  • Conflict of interest: R.E. Kanner has nothing to disclose.

  • Conflict of interest: J.A. Krishnan has nothing to disclose.

  • Conflict of interest: R. Paine III reports grants from NHLBI and COPD Foundation, during the conduct of the study; grants from Department of Veterans Affairs, outside the submitted work.

  • Conflict of interest: S.P. Peters, reports grants from NIH, NHLBI as the PI of the Wake Forest Clinical Site for the SPIROMICS COPD Program, during the conduct of the study.

  • Conflict of interest: S.I. Rennard is employed by AstraZeneca, Cambridge, UK and also retains Professorship and a part-time appointment at the the University of Nebraska Medical Center, Omaha, NE, USA.

  • Conflict of interest: P.G. Woodruff reports personal fees for consultancy from Theravance, AstraZeneca, Regeneron, Sanofi, Genentech, Roche and Janssen, outside the submitted work.

  • Conflict of interest: M. Arjomandi reports salary support from United States Department of Veterans Affairs, grants and salary support from United States National Institute of Health, during the conduct of the study.

  • Received November 21, 2018.
  • Accepted July 17, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence
View Full Text

INDIVIDUALS

Log in using your username and password

– ERS members: log in with your myERS username and password.
– Other users: log in with the credentials you created when you registered.
Forgot your user name or password?
Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

CONTACT US

If you have any questions about the ERS publications website, please contact journals@ersnet.org

PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 4 Table of Contents
European Respiratory Journal: 54 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS
Mehrdad Arjomandi, Siyang Zeng, Igor Barjaktarevic, R. Graham Barr, Eugene R. Bleecker, Russell P. Bowler, Russell G. Buhr, Gerard J. Criner, Alejandro P. Comellas, Christopher B. Cooper, David J. Couper, Jeffrey L. Curtis, Mark T. Dransfield, MeiLan K. Han, Nadia N. Hansel, Eric A. Hoffman, Robert J. Kaner, Richard E. Kanner, Jerry A. Krishnan, Robert Paine, Stephen P. Peters, Stephen I. Rennard, Prescott G. Woodruff
European Respiratory Journal Oct 2019, 54 (4) 1802214; DOI: 10.1183/13993003.02214-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS
Mehrdad Arjomandi, Siyang Zeng, Igor Barjaktarevic, R. Graham Barr, Eugene R. Bleecker, Russell P. Bowler, Russell G. Buhr, Gerard J. Criner, Alejandro P. Comellas, Christopher B. Cooper, David J. Couper, Jeffrey L. Curtis, Mark T. Dransfield, MeiLan K. Han, Nadia N. Hansel, Eric A. Hoffman, Robert J. Kaner, Richard E. Kanner, Jerry A. Krishnan, Robert Paine, Stephen P. Peters, Stephen I. Rennard, Prescott G. Woodruff
European Respiratory Journal Oct 2019, 54 (4) 1802214; DOI: 10.1183/13993003.02214-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Bronchial thermoplasty decreases airway remodelling by blocking HSP60 secretion and PRMT1
  • Pharmacogenomics of ICS and lung function decline in COPD
  • Reference genes determination for real-time PCR using induced sputum samples
Show more Original Articles

COPD

  • Pharmacogenomics of ICS and lung function decline in COPD
  • Inhaled AAT in patients with severe AATD and frequent exacerbations of COPD
  • Exacerbation action plans for patients with COPD and comorbidities
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2019 by the European Respiratory Society